Journal of Diagnostics Concepts & Practice ›› 2017, Vol. 16 ›› Issue (05): 472-476.doi: 10.16150/j.1671-2870.2017.05.005
• Experts forum • Previous Articles Next Articles
Received:2017-08-05
Online:2017-10-25
Published:2017-10-25
CLC Number:
| [1] Smith D, Yong K.Advances in understanding prognosis in myeloma[J]. Br J Haematol,2016,175(3):367-380. [2] 黎建云, 徐岚, 李军民, 等. PAD及VAD样-T方案治疗多发性骨髓瘤126例效果比较[J]. 白血病·淋巴瘤,2016,25(9):535-538. [3] 肖超, 常春康. 骨髓瘤骨病的病理机制进展与治疗[J]. 诊断学理论与实践,2015,14(4):375-380. [4] Rajkumar SV.Myeloma today: Disease definitions and treatment advances[J]. Am J Hematol,2016,91(1):90-100. [5] Palumbo A, Rajkumar SV, San Miguel JF, et al.International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation[J]. J Clin Oncol,2014,32(6):587-600. [6] Lahuerta JJ, Paiva B, Vidriales MB, et al.Depth of response in multiple myeloma: A pooled analysis of Three PETHEMA/GEM Clinical Trials[J]. J Clin Oncol,2017, 35(25):2900-2910. [7] Korde N, Roschewski M, Zingone A, et al.Treatment with Carfilzomib-Lenalidomide-Dexamethasone with lenalidomide extension in patients With smoldering or newly diagnosed multiple myeloma[J]. JAMA Oncol,2015,1(6):746-754. [8] Mateos MV, Martínez-López J, Hernández MT, et al.Sequential [9] Jakubowiak AJ, Dytfeld D, Griffith KA, et al.A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma[J]. Blood,2012,120(9):1801-1809. [10] Dytfeld D, Jasielec J, Griffith KA, et al.Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma[J]. Haematologica,2014,99(9):e162-e164. [11] Innao V, Allegra A, Russo S, et al. Standardisation of minimal residual disease in multiple myeloma[J/OL]. Eur J Cancer Care (Engl),2017-07-03[2017-08-05].https://www.ncbi.nlm.nih.gov/pubmed/28671297. [12] Gay F, Larocca A, Wijermans P, et al.Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients[J]. Blood,2011,117(11):3025-3031. [13] Rajkumar SV.Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management[J]. Am J Hematol,2016,91(7):719-734. [14] Landgren O, Owen RG.Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient[J]. Cytometry B Clin Cytom,2016,90(1):14-20. [15] Martinez-Lopez J, Lahuerta JJ, Pepin F, et al.Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma[J]. Blood,2014, 123(20):3073-3079. [16] Rawstron AC, Gregory WM, de Tute RM, et al. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction[J]. Blood,2015,125(12):1932-1935. [17] Paiva B, Vidriales MB, Cerveró J, et al.Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation[J]. Blood,2008,112(10):4017-4023. [18] Kumar S, Paiva B, Anderson KC, et al.International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma[J]. Lancet Oncol,2016,17(8):e328-e346. [19] Behdad A, Ross CW, Jacques J, et al.Utility of nine-color, 11-parameter flow cytometry for detection of plasma cell neoplasms: a comparison with bone marrow morphologic findings and concurrent M-protein studies in serum and urine[J]. Am J Clin Pathol,2014,142(3):398-410. [20] Paiva B, Martinez-Lopez J, Vidriales MB, et al.Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma[J]. J Clin Oncol,2011,29(12):1627-1633. [21] Gonsalves WI, Rajkumar SV, Dispenzieri A, et al.Quantification of circulating clonal plasma cells [22] Gonsalves WI, Morice WG, Rajkumar V, et al.Quantification of clonal circulating plasma cells in relapsed multiple myeloma[J]. Br J Haematol,2014,167(4):500-505. [23] Flores-Montero J, Sanoja-Flores L, Paiva B, et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma[J/OL]. Leukemia,2017-03-10[2017-08-05].https://www.ncbi.nlm.nih.gov/pubmed/28104919. [24] Puig N, Sarasquete ME, Balanzategui A, et al.Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry[J]. Leukemia,2014,28(2):391-397. [25] Drandi D, Kubiczkova-Besse L, Ferrero S, et al.Minimal residual disease detection by droplet digital PCR in multiple myeloma, mantle cell lymphoma, and follicular lymphoma: A comparison with real-time PCR[J]. J Mol Diagn,2015,17(6):652-660. [26] Sata H, Shibayama H, Maeda I, et al.Quantitative polymerase chain reaction analysis with allele-specific oligonucleotide primers for individual IgH VDJ regions to evaluate tumor burden in myeloma patients[J]. Experimental hematology,2015,43(5):374-381. [27] Ladetto M, Brüggemann M, Monitillo L, et al.Next-gene-ration sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders[J]. Leukemia,2014,28(6):1299-1307. [28] Usmani SZ, Mitchell A, Waheed S, et al.Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3[J]. Blood,2013,121(10):1819-1823. [29] Zamagni E, Nanni C, Mancuso K, et al.PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma[J]. Clin Cancer Res,2015,21(19):4384-4390. [30] Lapa C, Knop S, Schreder M, et al.11C-Methionine-PET in multiple myeloma: Correlation with clinical parameters and bone marrow involvement[J]. Theranostics,2016,6(2):254-261. [31] Philipp-Abbrederis K, Herrmann K, Knop S, et al. [32] Dimopoulos MA, Hillengass J, Usmani S, et al.Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement[J]. J Clin Oncol,2015,33(6):657-664. [33] Barnidge DR, Dasari S, Botz CM, et al.Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy[J]. J Proteome Res,2014,13(3):1419-1427. [34] Barnidge DR, Tschumper RC, Theis JD, et al.Monitoring M-proteins in patients with multiple myeloma using heavy-chain variable region clonotypic peptides and LC-MS/MS[J]. J Proteome Res,2014,13(4):1905-1910. [35] Bergen HR 3rd, Dasari S, Dispenzieri A, et al. Clonoty-pic light chain peptides identified for monitoring minimal residual disease in multiple myeloma without bone marrow aspiration[J]. Clin Chem,2016,62(1):243-251. [36] Martínez-López J, Paiva B, López-Anglada L, et al.Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality[J]. Blood,2015,126(7):858-862. [37] Munshi NC, Avet-Loiseau H, Rawstron AC, et al.Associa-tion of minimal residual disease with superior survival outcomes in patients with multiple myeloma: A meta-analysis[J]. JAMA Oncol,2017,3(1):28-35. [38] Paiva B, Chandia M, Puig N, et al.The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma[J]. Haematologica,2015,100(2):e53-e55. |
| [1] | . [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(02): 195-198. |
| [2] | . [J]. Journal of Diagnostics Concepts & Practice, 2019, 18(06): 685-671. |
| [3] | . [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(05): 468-471. |
| [4] | CAO Yafeng, WANG Jing, GU Jun, LU Hongyu, XUN Jie, LIU Yuanfang, WANG Yan, WANG Jin, CHEN Yu, CHEN Yubao, LI Jiaming, HAO Jie, MI Jianqing, CHEN Mei. Analysis of peripheral neuropathy following treatment with bortezomib in 114 newly-diagnosed multiple myeloma patients [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(05): 492-497. |
| [5] | . [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(05): 455-459. |
| [6] | . [J]. Journal of Diagnostics Concepts & Practice, 2016, 15(06): 545-549. |
| [7] | . [J]. Journal of Diagnostics Concepts & Practice, 2016, 15(06): 556-560. |
| [8] | . [J]. Journal of Diagnostics Concepts & Practice, 2016, 15(06): 561-566. |
| [9] | . [J]. Journal of Diagnostics Concepts & Practice, 2016, 15(06): 567-572. |
| [10] | . [J]. Journal of Diagnostics Concepts & Practice, 2016, 15(06): 573-577. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
